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Objectives The aim of this study was to assess the influence of enrolling site location and enrollment performance on the
generalizability of STICH (Surgical Treatment for Ischemic Heart Failure) trial results.
Background The international STICH trial seeks to define the role of cardiac surgery for patients with ischemic cardiomyopathy.
Methods Baseline characteristics of 2,136 randomized STICH patients were entered into a multivariate equation created
using the Duke Databank for Cardiovascular Diseases to predict their 5-year risk for death without cardiac sur-
gery. Patients ordered by increasing predicted risk were assigned to 1 of 32 risk at randomization (RAR) groups
created to share one-thirty-second of total predicted deaths. Numbers of patients sharing the same RAR group
were compared between higher and lower enrolling site groupings and for countries tending to enroll high- or
low-risk patients.
Results Country of enrollment was a stronger determinant of risk diversity than site enrollment performance among pa-
tients enrolled at 127 sites in 26 countries. Mean RAR differences among countries ranged from 9.4 (Singapore)
to 18.6 (Germany). However, 1,614 of 2,136 patients (76%) from countries enrolling lower-risk patients shared
the same RAR group with patients from countries enrolling higher-risk patients. Baseline characteristics respon-
sible for risk differences of patients enrolled in the 2 country groupings were sufficiently similar to exert little
influence on clinical decision making.
Conclusions STICH randomized patients are characterized by a continuous spectrum of risk, without discordant dominance
from any site or country. Clinical site diversity promises to enhance the generalization of STICH trial results to a
broad population of patients with ischemic cardiomyopathy. (Comparison of Surgical and Medical Treatment for
Congestive Heart Failure and Coronary Artery Disease; NCT00023595) (J Am Coll Cardiol 2010;56:490–8)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.102r
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mhe National Institutes of Health–funded international
TICH (Surgical Treatment for Ischemic Heart Failure)
rial addresses 2 hypotheses to assess the value of cardiac
urgery in patients with ischemic cardiomyopathy (1). The
rom the *Division of Cardiothoracic Surgery/Department of Surgery, †Division of
ardiovascular Medicine/Department of Medicine, and the ‡Department of Surgery,
uke University, Durham, North Carolina; §Duke Clinical Research Institute,
urham, North Carolina; Green Lane Cardiovascular Service, Auckland City
ospital, Auckland, New Zealand; ¶Department of Health Services Research,
uke-NUS, Singapore; #Department of Medicine-Cardiovascular Disease, Wash-
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nstitute, National Institutes of Health, Bethesda, Maryland; and the ‡‡Institut de
ardiologie de Montreal, University of Montreal, Montreal, Quebec, Canada. This
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009, accepted November 3, 2009.ecently reported outcome of the surgical ventricular recon-
truction (SVR) hypothesis confirmed that adding SVR to
oronary artery bypass grafting (CABG) in patients with
nterior left ventricular (LV) dysfunction decreased LV
olume more than CABG alone but did not reduce death or
ardiac hospitalization (2). Cardiovascular specialists have
See page 508
aised questions about whether the spectrum of severity of
isease at the time of randomization was sufficiently broad
o include all patients who might receive survival benefit
rom SVR (3). Data from patients now being followed in
he surgical revascularization hypothesis will definitively
nswer whether or not CABG added to evidence-based
edical therapy (MED) increases the survival of patients
ith ischemic cardiomyopathy. This answer will clarify
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August 3, 2010:490–8 The STICH Trial Enrollmenthether an ischemia diagnosis and interventional treatment
hould be pursued in patients presenting with heart failure
ymptoms or asymptomatic systolic dysfunction. The impor-
ance of STICH trial findings to guide appropriate care
ecisions for future patients demands an answer to the ques-
ion: how generalizable are STICH trial results to the patients
see?
The STICH protocol enrollment criteria ensured patient
afety and excluded patients without ischemic cardiomyop-
thy as the most likely cause of death during follow-up.
hereafter, responsible physicians selected 1 of 3 random-
zation strata, each of which included possible randomiza-
ion to a cardiac surgical option with significant short-term
isk. Patient enrollment was difficult. Variation in equipoise
mong clinicians and clinical site diversity of structure and
are processes produced a broad range of randomization
ates. Incremental geographic expansion over 3 years caused
nrollment duration to vary among sites. Clinical site
ocation has been shown to influence characteristics of
nrolled populations (4). That STICH was among the top
0 of 129 ongoing clinical trials (7.9%) during 2005 ran-
omizing patients in 20 or more countries (5) emphasizes
he need to assess whether enrolling site diversity helped or
indered the generalization of STICH conclusions. The
iversity of STICH sites could have aggregated multiple
ubgroups into discontinuous patient groupings with dis-
imilar risk. Alternatively, random individual patient diver-
ity both within and among sites could produce a population
ith a smooth gradation of risk severity. A patient-based
etric of baseline risk is needed to document the influence
f enrollment decisions made by many physicians in differ-
nt clinical care environments.
This report describes the STICH risk at randomization
RAR) index, which reflects baseline clinical risk of each
atient in context with the full risk spectrum of all random-
zed patients. Clinical site enrollment rates and geographic
ocation influence on the total randomized patient cohort
isk spectrum are compared using the numbers of random-
zed patients who share the same RAR index number when
rouped by clinical site characteristics. Clinical data tabu-
ated from RAR groups created to show the greatest
aseline risk discordance place the variability among enroll-
ng sites in clinical context.
ethods
linical site and patient recruitment. In 2002, 23 U.S., 7
anadian, and 2 European clinical sites selected for exper-
ise in clinical research and outstanding care of patients with
schemic cardiomyopathy were activated. Persistently low
atient enrollment required incremental expansion that
oncluded in 2005 with 171 activated clinical sites. Clinical
ites were expected to enroll patients into both hypotheses,
xcept for the last sites invited in Argentina, India, and the
.K. These sites were recruited to enroll patients only intohe surgical revascularization hypothesis because their help aas not needed to attain the
,000-patient SVR hypothesis
ecruitment goal. During the 3
ears of incremental expansion,
4 activated clinical sites were
eactivated by mutual consent
ecause of their inability to enroll
ny patient.
LV ejection fraction 0.35 and
oronary artery disease (CAD)
menable to CABG were entry
riteria for all STICH patients.
ajor cardiac disease exclusions
ere a recent myocardial infarction
nd need for aortic valve replace-
ent. Any noncardiac disease sufficiently severe to dominate
xpected 3-year longevity excluded patients. Study design
equired all STICH patients to receive MED. Patients with
anadian Cardiovascular Society class III or greater ongoing
ngina on MED and/or 50% left main stenosis were not
ligible for randomization to MED as their only treatment.
ligibility for SVR required dominant anterior akinesia or
yskinesia amenable to SVR. Patients ineligible for SVR but
ligible to receive MED with or without CABG were ran-
omized in stratum A. Patients ineligible for MED alone but
ligible to receive CABG with or without SVR were random-
zed in stratum C. Patients eligible for all 3 treatments were
andomized in stratum B. All stratum A and stratum B
atients randomized to MED with or without CABG were
nalyzed in the surgical revascularization hypothesis. All stra-
um C patients and stratum B patients randomized to CABG
ith or without SVR were analyzed in the SVR hypothesis.
The clinical judgment of physicians and surgeons respon-
ible for care of STICH-eligible patients determined the
nrollment stratum offered for patient consent under the
versight of the ethics committee at each site. The primary
thical concern guiding equipoise for randomization was to
ffer patients treatment combinations judged to have similar
ong-term mortalities. Relative benefits of treatment com-
inations offered within each enrollment stratum might
iffer among STICH sites. The randomization process
tratified treatment assignment by site. Whereas it is not
ossible to know the underlying enrolling physician judg-
ent used to choose the enrollment stratum, it is possible to
ap the individual clinical characteristics of enrolled pa-
ients to provide evidence of the spectrum of disease severity
roduced by choices made.
reation of the RAR index. Three Duke Databank for
ardiovascular Diseases CAD prognosis publications (6–8)
dentified candidate variables used to create a Cox multi-
ariate regression equation predictive of time to death in
21 STICH-eligible MED Duke Databank for Cardiovas-
ular Diseases patients during 5.5 years of follow-up.
rognostic baseline clinical variables in descending order of
mportance for predicting time to death in this cohort over
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
LV  left ventricular
MED  evidence-based
medical therapy
RAR  risk at
randomization
SVR  surgical ventricular
reconstructionmean follow-up of 5 years were age, renal disease (creat-
i
C
(
t
d
r
p
d
c
M
d
d
s
w
p
p
i
p
f
m
g
g
S
C n.
492 Jones et al. JACC Vol. 56, No. 6, 2010
The STICH Trial Enrollment August 3, 2010:490–8nine 1.5 mg/dl), heart failure, ejection fraction, Duke
AD index, mitral insufficiency, and cerebrovascular disease
Table 1). Individual STICH patient baseline values for
hese variables entered into the multivariate equation pro-
uced a probability of death for each STICH patient that
anged from 0.18387 to 0.99949. The STICH patients were
laced in ascending order of their individual prediction of
eath. All predicted death estimates summed to 1,001.648
orresponded to a 5-year mortality of 0.469, assuming only
ED, not surgical treatment, for the 2,136 STICH ran-
omized patients. Using least squares analysis to minimize
1 2 3 4 5 6 7 8 9 10 11 12 13 14 1
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Figure 1 RAR Development
The continuous green line represents the 2,136 data points of individual patient m
dicted deaths for all patients in each risk at randomization (RAR) group. The blue
lines represent the RAR group mortality assigned to each patient in each RAR grou
ignificant Covariates in the RAR Multivariate ModelTable 1 Significant Covariates in the RAR ultivariate Model
Variable Parameter Estimate Standard Err
Age 0.27836 0.04339
Renal disease 1.27632 0.26594
Heart failure 0.10669 0.02768
Ejection fraction 0.11904 0.03190
CAD index 0.00582 0.00184
Mitral insufficiency 0.10521 0.03559
History of cerebrovascular disease 0.26897 0.10504
AD  coronary artery disease; NYHA  New York Heart Association; RAR  risk at randomizatioifferences between groups, 32 groups were created to each
hare one-thirty-second of total predicted deaths as close as
as possible with the constraint that the exact risk of each
atient had to be assigned to only 1 group. The numbers of
atients in groups 1 to 32 deceased as the predicted risk
ncreased, except for groups 31 and 32, which each had 32
atients (Fig. 1). Total predicted deaths per group ranged
rom a minimum of 30.89 (RAR group n  31) to a
aximum of 31.67 (RAR group n  28). The average
roup mortality ranged from 0.228 in group 1 to 0.989 in
roup 32. By assigning the average group mortality to each
0 
20 
40 
60 
80 
100 
7 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
% 
tion (RAR) Index 
ty predicted from the multivariate model. The green boxes represent total pre-
depict the total number of patients in each RAR group. The interrupted orange
Chi-Square p Value Hazard Ratio Variable Definition
41.1562 0.0001 1.321 Yrs (HR by 10 yrs)
23.0321 0.0001 3.583 Creatinine 1.5 mg/dl
14.8579 0.0001 1.113 NYHA functional class
13.9255 0.0002 0.888 % (HR per 5)
10.0175 0.0016 1.006 0–100
8.7393 0.0031 1.111 0 (none)–4 (severe)
6.5565 0.0105 1.309 Stroke or equivalent5 16 1
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August 3, 2010:490–8 The STICH Trial Enrollmentatient in each group, every patient carries a marker of his or
er predicted risk in the context of the entire randomized
opulation. The RAR of each patient provides a tool to
valuate the impact of clinical site location and enrollment
erformance on the spectrum of risk of all patients enrolled.
reation of the RAR index only ordered patients by
aseline risk, without disrupting randomized status within
AR groups. Therefore, each patient may be considered to
e an interchangeable courier of equivalent baseline risk
hen compared by clinical site characteristics within his or
er RAR grouping.
nalysis of clinical site location and performance on risk
pectrum of enrolled patients. The RAR profiles of 2
ichotomous separations of the 2,136 STICH total patients
ere compared for the numbers of patients who shared each
AR interval. The RAR profile of 1,057 patients enrolled
y the 13 highest enrolling sites was compared to the RAR
rofile of 1,078 patients from the 114 lowest enrolling sites.
o evaluate the influence of enrolling country on the risk
istribution of patients, a mean patient-weighted RAR was
alculated to reflect the average risk of all patients enrolled
n each country. The sum resulting from multiplying the
AR index number of each patient enrolled in each country
hen divided by total number of all enrolled patients in each
ountry provided the mean patient-weighted RAR for that
ountry. Patients from 3 countries (Belgium, Greece, and
urkey) enrolling only 1 patient each were grouped with the
patients enrolled in Malaysia to provide a single patient-
eighted mean RAR for the 4 lowest enrolling countries.
rranging countries in ascending order of patient-weighted
ean RAR identified Sweden (n  22) to separate 7
ountries with lower mean RAR that enrolled 1,057 pa-
ients from the 18 countries with higher mean RAR that
nrolled 1,057 patients. The 7 lower-risk patients from
weden added to the 1,057 patients from lower-risk coun-
ries brought the number of patients in the lower-risk
ountry grouping to 1,064. The 15 higher-risk patients
dded to the 1,057 patients from higher-risk countries
rought the total to 1,072 patients in the higher-risk cohort.
n RAR zones 1 to 12, clinical sites with lower mean RAR
nrolled most patients. In RAR zones 22 to 32, countries
ith higher mean RAR enrolled most patients. In RAR
ones 13 to 21, both country groupings enrolled similar
atients. For each of these 3 RAR zone groupings, baseline
linical characteristics of patients from countries tending to
nroll high-risk patients were compared with those of
atients from countries tending to enroll low-risk patients.
esults
atient enrollment. Between July 24, 2002, and May 5,
007, 127 sites in 26 countries randomized 2,136 patients.
n the basis of clinical decisions and protocol guidelines,
,277 of 2,136 randomized patients (60%) (stratum A 
tratum B) were eligible for MED alone, and 1,075 of the
,136 patients (50%) (stratum B  stratum C) were SVR tligible (Fig. 2). A relatively smooth profile of decline in the
umber of patients was observed throughout the RAR risk
pectrum (Fig. 3). The median age steadily increased from
8 to 74 years, and the median ejection fraction decreased
rom 0.30 to 0.20 over the 32 RAR groups.
The same RAR group was shared by 890 of the 1,057
atients (84%) from higher enrolling sites and 82% of 1,078
atients from lower enrolling sites (Fig. 4). The 167
nmatched patients from the higher enrolling sites were
redominantly lower-risk patients. The 189 unmatched
atients from the lower enrolling sites were predominantly
igher-risk patients. There was no consistent relationship
etween total patient enrollment in each country and the
atient-weighted mean RAR index by enrolling country
Fig. 4). Poland and Russia dominated the enrollment of
ower-risk patients, and the U.S. and Canada led countries
nrolling higher-risk patients. RAR profiles showed that
07 of 1,064 patients (76%) from countries enrolling lower-
isk patients matched 807 of 1,072 patients (75%) from
ountries enrolling higher-risk patients (Fig. 5). However,
he RAR profile identified 3 patterns of unmatched pa-
ients. In RAR groups 1 to 12, all unmatched patients were
rom countries enrolling lower-risk patients. RAR groups
3 to 21 showed similar numbers of unmatched patients
rom both country groupings. In RAR groups 22 to 32, all
nmatched patients were from countries enrolling higher-
isk patients. Baseline clinical characteristics tabulated for
hese 3 RAR patient groupings demonstrated statistically
ignificant differences between patients in the lowest and
ighest RAR groupings, with less difference among patients
n RAR groups 13 to 21 (Table 2). However, the magnitude
f statistically significant differences of patients related to
ountry of enrollment appeared sufficiently small to be
f little clinical significance in application of STICH re-
ults to care decisions for future patients with ischemic
ardiomyopathy.
iscussion
he Northern New England Cardiovascular Disease Study
roup identified patients with poor LV function to have the
reatest inconsistency of CABG use compared with guide-
ine recommendations (9). STICH investigators experi-
nced this divergence of opinion when patients who were
TICH eligible by protocol were presented at investigator
eetings. Difference in zones of equipoise among physi-
ians responsible for enrolling patients at individual sites
ombined to produce a smooth risk profile for the entire
TICH population. The 4-fold decline in numbers of
atients over the 32 RAR groups created with equivalent
redicted deaths produced a STICH patient risk profile
amiliar to clinicians. Ischemic cardiomyopathy as the high-
st risk subset of all chronic CAD diagnoses includes a
apidly declining number of patients in each RAR group
hat reflects the highest risk tail of a normal distribution of
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The STICH Trial Enrollment August 3, 2010:490–8ll patients with CAD truncated by an ejection fraction
0.35 applied as a STICH entry criterion.
Enrollment performance varied greatly among sites and
as strongly related to baseline clinical risk. The highest
nrolling sites tended to enroll more low-risk patients. The
owest-enrolling sites tended to enroll more high-risk pa-
ients. The patient risk zone that corresponded to the
quipoise zone of the responsible physician appeared to be
he strongest determinant of baseline risk of enrolled pa-
ients at a site. The profile of the RAR patient distribution
uggests that small differences in equipoise windows posi-
ioned toward the low- or high-risk direction could produce
ubstantial changes in numbers of patients considered eligi-
le for randomization. Many more low-risk patients than
igh-risk patients were available if sites were willing to ran-
omize them. However, RAR data confirm that 85% of
nrolled patients had similar predicted risk even when clinical
ites were grouped by those sites with lowest or highest
nrollment performance. Moreover, both site performance
roupings enrolled some patients into each RAR group.
Country differences in population demographics also may
nfluence the numbers of low- or high-risk patients present-
MED
+
CABG
(610)
CAD, EF  
Eligible for MED-onl
Eligible for SVR?
Surgical Revascularization
Hypothesis n = 1212
MED
(602)
Stratum A
n = 1061
1
MED
(527)
2
MED
+
CABG
(534)
Stratum B
n = 216
3
MED
(75)
5
MED
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+
SVR
(65)
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MED
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CABG
(76)
+ +
+ +
No Yes
Yes
Figure 2 Schema of Patient Enrollment
This schematic depiction of the STICH (Surgical Treatment for Ischemic Heart Failu
assignments were evidence-based medical therapy (MED) only for 602 patients, co
surgical ventricular reconstruction (SVR) added to MED for 501 patients. The 76 s
the surgical revascularization hypothesis and the SVR hypothesis. Therefore, 2,13
analysis of either or both hypotheses. CAD  coronary artery disease; EF  ejecting with STICH eligibility criteria. The World Health prganization has reported age-standardized mortality rates
or cardiovascular disease per 100,000 population to be 324
or Poland and 688 for Russia, the 2 highest enrolling
ountries of the 7 countries tending to enroll low-risk
atients, in contrast to rates of 188 for the U.S. and 141 for
anada, the 2 highest enrolling of the 18 countries tending
o enroll more high-risk patients. Country demographics,
ealth care availability, and equipoise differences among
hysicians most likely contributed in varying degrees to
roduce observed variation in patient risk among enrolling
ountries. However, sufficient similarity of patient baseline
isk among all enrolling countries has been demonstrated to
uggest that STICH enrollment of patients in 26 countries
hould enhance the generalization of STICH trial results to
broad spectrum of future patients with ischemic cardio-
yopathy throughout the world.
The use of a multivariate equation to stratify baseline risks of
andomized patients into low-risk, middle-risk, and high-risk
roups was first reported by the Veterans Administration
ooperative Study Group in 1981 (10). Treatment effect was
onfined to only the high-risk cohort. This early work changed
atient selection criteria for CABG from low- to high-risk
Randomized Patients
Numbers for Analysis
by HypothesisD
BG
9)
ment?
Not in trial
No
 Hypothesis
1000
MED
+
CABG
+
SVR
(501)
ible for SVR?
ratum C
n = 859
Yes
D
BG
3)
7
MED
+
CABG
+
SVR
(436)
2136 Randomized pts=
  602 MED only
1033 CABG added
  501 CABG+SVR added
=
No
al design includes numbers of patients randomized to each stratum. Treatment
y artery bypass grafting (CABG) added to MED for 1,033 patients, and CABG and
B patients assigned to MED plus CABG treatment were used to address both
omized patients provided 2,212 patients with potential for primary end points for
tion.ME
+
CA
(49
0.35
y treat
SVR
n = 
Elig
St
6
ME
+
CA
(42
re) tri
ronar
tratum
6 rand
on fracatients and set the precedent for modeling of baseline
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August 3, 2010:490–8 The STICH Trial EnrollmentFigure 3 Patients and Corresponding Clinical Characteristics by RAR
Histogram depicting individual patients at each RAR interval. The corresponding median age, ejection fraction (EF), and Duke coronary artery disease (CAD) index for each risk at
randomization (RAR) group and the percent of patients in each RAR group with baseline creatinine (CR) 1.5 mg/dl, New York Heart Association (NYHA) functional class III to IV
heart failure (HF), diabetes, mitral regurgitation 3 to 4, and vascular disease provided a comprehensive summary of the components of risk for the entire population.
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Figure 4 Country Enrollment by Enrolled Cohort Mean RAR
Countries ranked by the patient-weighted risk at randomization (RAR) mean show a 2-fold range of difference from the lowest mean of 9.4 (Singapore) to the highest
mean of 18.6 (Germany). The number of patients enrolled in each country and cumulative patient enrollment by increasing RAR show the diversity of enrollment perfor-
mance by country throughout the spectrum of patient risk of enrolling countries. The patient-weighted mean RAR index was calculated by multiplying the number of
patients enrolled by each country by the index number of each RAR interval. The sum of these products was divided by the total number of patients enrolled by that
country to produce the patient-weighted mean RAR. *4 countries with few patients (Belgium 1, Greece 1, Turkey 1, Malaysia 4) combined. SVR  surgical ventricular
reconstruction.
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August 3, 2010:490–8 The STICH Trial Enrollmentharacteristics of randomized patients to define their relative
isk. The present work represents the first individualized
atient-based RAR index used to describe the full risk spec-
rum of a randomized trial cohort.
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Patients
From
Countries
Enrolling
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Patients
(n = 1064)
Patients
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Countries
Enrolling
Higher-Risk
Patients
(n = 1072)
807 (76%) of 1064 patients from countries enrolling low
match 807 patients enrolled by countries enrolling high
257 (24%) of 1064 patients
unmatched by patients enro
265 (25%) of 1072 patients
unmatched by patients enro
807 (75%) of 1072 patients from countries enrolling hig
match 807 patients enrolled by countries enrolling lowe
Figure 5 RAR Profile by Country Mean Patient Risk
A total of 1,614 of 2,136 patients (76%) shared the same risk at randomization (R
among countries on the basis of the average baseline risk of patients randomized
mean RAR, and RAR groups 22 to 32 included more patients from countries with
bution of patients from the 2 country groupings of sites. The baseline characterist
omparison of Baseline Clinical Characteristics in 3 RAR Groupingatient-Weighted M a RAR (Low-RAR Countr e ) With Clinical SitesTable 2 Comparison of Baseline Clinical Characteristics in 3 RARPatient-Weighted Mean RAR (Low-RAR Countries) With C
Baseline Clinical
Characteristic
RAR Groups 1 to 12
Patients From
Low-RAR
Countries
(n  684)
Patients From
High-RAR
Countries
(n  432) p Value
Patie
Lo
Co
(n
Age (yrs) 55.3 7.6 57.2 8.2 0.001 63.
LVEF (%) 28.5 5.2 26.8 5.8 0.001 26.
CAD severity index 54.1 19.3 51.2 18.0 0.012 71.
Chronic renal insufficiency 0 (0.0%) 0 (0.0%) — 0
NYHA functional class
I 87 (12.7%) 64 (14.8%) 0.001 15
II 401 (58.6%) 208 (48.2%) 128
III 193 (28.2%) 150 (34.7%) 105
IV 3 (0.4%) 10 (2.3%) 4
Mitral regurgitation
0 222 (32.5%) 219 (50.7%) 0.001 43
1 282 (41.2%) 158 (36.6%) 118
2 46 (6.7%) 27 (6.2%) 44
3 14 (2.1%) 3 (0.7%) 10
4 120 (17.5%) 25 (5.8%) 37
Diabetes 166 (24.3%) 157 (36.3%) 0.001 93ata are expressed as mean  SD or as n (%).
CAD  coronary artery disease; HF  heart failure; LVEF  left ventricular ejection fraction; NYHA  Ntudy limitations. Predicted mortality of STICH-eligible
atients in the Duke Databank for Cardiovascular Diseases
ay not accurately reflect the mortality of STICH patients
reated in other health care settings. However, the RAR
17 18 19 20 21 22 23 24 25 26 27 28  29 30 31 32 RAR Index
patients 
atients
d by countries enrolling lower-risk patients 
 countries enrolling higher-risk patients
d by countries enrolling higher-risk patients
 countries enrolling lower-risk patients
 patients 
atients
rouping despite the intentional creation of 2 cohorts to maximize imbalance
groups 1 to 12 included more patients from countries with low patient-weighted
tient-weighted mean RAR. RAR groups 10 to 21 reflected the most even distri-
patients in these 2 groupings are compared in Table 1.
Enrollment by Clinical Sites in Lowh Patient-Weighted Mean RAR (High-RAR Countries)pings by Enrollme t by Clinical Sites in Low
l Sites in High Patient-Weighted Mean RAR (High-RAR Countries)
RAR Groups 13 to 21 RAR Groups 22 to 32
om
s
)
Patients From
High-RAR
Countries
(n  308) p Value
Patients From
Low-RAR
Countries
(n  128)
Patients From
High-RAR
Countries
(n  332) p Value
3 66.4 7.8 0.001 66.5 7.4 68.3 8.9 0.026
8 26.1 6.1 0.532 25.3 5.9 23.8 6.3 0.021
.7 66.0 20.9 0.004 78.1 18.4 74.4 20.1 0.067
) 0 (0.0%) — 35 (27.3%) 137 (41.3%) 0.006
) 32 (10.4%) 0.002 6 (4.7%) 13 (3.9%) 0.039
%) 135 (43.8%) 50 (39.1%) 93 (28.0%)
%) 124 (40.3%) 64 (50.0%) 181 (54.5%)
) 17 (5.5%) 8 (6.2%) 45 (13.6%)
%) 109 (35.4%) 0.001 20 (15.6%) 85 (25.6%) 0.003
%) 124 (40.3%) 40 (31.2%) 125 (37.7%)
%) 49 (15.9%) 34 (26.6%) 79 (23.8%)
) 6 (2.0%) 16 (12.5%) 17 (5.1%)
%) 20 (6.5%) 18 (14.1%) 26 (7.8%)
%) 141 (45.8%) 0.034 65 (50.8%) 177 (53.3%) 0.62615 16
er-risk 
er-risk p
 enrolle
lled by
 enrolle
lled by
her-risk
r-risk p
AR) g
. RAR
high pa
ics ofs byin HigGrou
linica
nts Fr
w-RAR
untrie
 252
3 7.
5 5.
1 20
(0.0%
(5.9%
(50.8
(41.7
(1.6%
(17.1
(46.8
(17.5
(4.0%
(14.7
(36.9ew York Heart Association; RAR  risk at randomization.
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The STICH Trial Enrollment August 3, 2010:490–8rouping order of patients was independent of the numeric
ccuracy of the risk prediction.
RAR development included site-reported ejection frac-
ion as the only assessment of LV function. Core laboratory
ssessments of global and regional LV function reported
ithout knowledge of patient treatment will be used to
ssess the generalizability of STICH results on the basis of
he severity of abnormality represented by the SVR hypoth-
sis patients. Many patient-specific clinical variables that in-
uence decisions for cardiac surgery, such as conduit availabil-
ty and the suitability of coronary arteries for CABG, were not
eported for STICH patients. However, all patients random-
zed were assessed as eligible for either CABG alone or CABG
ith SVR by STICH surgeons at each clinical site.
onclusions
he RAR index methodology provides a clinically useful
uantitation of the baseline risk spectrum of patients.
linical site location introduced greater variation on the
rofile of baseline clinical risk than enrollment performance.
owever, 76% of patients shared the same risk profile when
rouped by randomization in countries that enrolled more
igh- or low-risk patients. Differences in the baseline
haracteristics causing site-related differences in the RAR
rofile were modest and unlikely to hinder the generaliz-
bility of STICH results. Diversity among patients random-
zed by 127 STICH clinical sites appears more likely to
nhance the generalizability of STICH trial results.
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